NCT03868605

Brief Summary

Most of the cancers develop from the adenomatous polyps. The therapeutic methods have been established already - endoscopic polypectomy (EPE) for stalked polyps and endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for non-pedunculated polyps. EMR is preferred in European countries over ESD because of its higher feasibility. However, the local residual neoplasia (LRN) after EMR has been reported in 14 - 24 % cases. There is a higher LRN risk in sessile polyps which do not elevate sufficiently after the submucosal injection (non-lifting sign) and the piece-meal resection needs to be used. Therefore, the new method of endoscopic full-thickness resection (FTR) has been developed to resect these lesions.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 7, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 11, 2019

Completed
3 months until next milestone

Study Start

First participant enrolled

May 31, 2019

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

April 20, 2022

Status Verified

April 1, 2022

Enrollment Period

3 years

First QC Date

March 7, 2019

Last Update Submit

April 12, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of R0 procedures

    proportion of patients with resection specimens with negative horizontal and vertical margins confirmed by histopathology

    3 months

Secondary Outcomes (1)

  • Proportion of curative resections

    12 months

Study Arms (2)

EMR/ESD

EXPERIMENTAL

Standard EMR or ESD technique

Device: EMR and ESD

Over- the- scope full- thickness resection device

EXPERIMENTAL

Endoscopic full thickness resection

Device: Over- the- scope full- thickness resection device

Interventions

Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife

EMR/ESD

Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device

Over- the- scope full- thickness resection device

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age ≥ 18 years
  • colorectal lesions of 10-25 mm size with positive non-lifting sign
  • signed informed consent with the study and with colonoscopy

You may not qualify if:

  • age \< 18 years
  • lesions \> 25 mm
  • pedunculated polyps
  • colorectal stenosis
  • colonoscopy contraindication
  • severe acute inflammatory bowel disease
  • severe comorbidities
  • patient not able to sign the informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Military University Hospital

Prague, Czechia

RECRUITING

MeSH Terms

Conditions

PolypsColonic Neoplasms

Interventions

Radiotherapy

Condition Hierarchy (Ancestors)

Pathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Stepan Suchanek, MD., Ph.D

    Military University Hospital, Prague

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Stepan Suchanek, MD., Ph.D.

CONTACT

Michal Voska, MD.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Endoscopy unit

Study Record Dates

First Submitted

March 7, 2019

First Posted

March 11, 2019

Study Start

May 31, 2019

Primary Completion

June 1, 2022

Study Completion

December 1, 2022

Last Updated

April 20, 2022

Record last verified: 2022-04

Locations